STOCK TITAN

Livanova Plc Stock Price, News & Analysis

LIVN Nasdaq

Welcome to our dedicated page for Livanova Plc news (Ticker: LIVN), a resource for investors and traders seeking the latest updates and insights on Livanova Plc stock.

LivaNova PLC (LIVN) is a global leader in medical technology innovation, specializing in life-supporting cardiopulmonary solutions and neuromodulation therapies. This dedicated news hub provides investors and healthcare professionals with essential updates on the company’s clinical advancements, regulatory milestones, and strategic initiatives.

Track all official LivaNova press releases, earnings reports, and product development announcements in one centralized resource. Our curated news feed covers critical developments including FDA clearances, international expansion efforts, and partnerships shaping the future of cardiac surgery and neurological treatment technologies.

Key updates feature progress in extracorporeal circulation systems, enhancements to vagus nerve stimulation therapies, and sustainability initiatives across global manufacturing operations. The platform serves as a vital tool for monitoring how LivaNova’s innovations in heart-lung machines and depression treatment devices impact both patient outcomes and shareholder value.

Bookmark this page for immediate access to verified information about LIVN’s market position, intellectual property developments, and leadership changes. Stay informed about the medical technology pioneer driving advancements in critical care through its merged heritage of European and American engineering excellence.

Rhea-AI Summary

LivaNova PLC (NASDAQ: LIVN) will host a conference call on February 22, 2023, at 1 p.m. London time to discuss its fourth-quarter and full-year 2022 results. The results will be released prior to the call. The audiocast can be accessed via www.livanova.com/events. Participants can join via telephone by calling +1 844 200 6205 (U.S.) or +1 929 526 1599 (international), with access code 041577. A replay will be available for 90 days after the call. LivaNova is a global leader in medical technology, focused on delivering innovative solutions for patients and healthcare systems worldwide.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.37%
Tags
-
Rhea-AI Summary

LivaNova PLC (NASDAQ: LIVN) has received a close-out letter from the FDA regarding the Warning Letter issued on December 29, 2015, related to its Munich facility and 3T Heater-Cooler device. This closure signifies the successful implementation of corrective actions by LivaNova. CEO Damien McDonald expressed gratitude for the FDA's collaboration and the efforts of the LivaNova team during this process. The company emphasized its commitment to quality and safety in its operations.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.61%
Tags
none
-
Rhea-AI Summary

LivaNova PLC (NASDAQ: LIVN) announced its participation in the American Epilepsy Society 2022 Annual Meeting, taking place from December 2-6 in Nashville, Tennessee. The company will showcase seven scientific posters focused on advancing neuromodulation and improving treatment for drug-resistant epilepsy. Dr. Bryan Olin emphasized the company's commitment to enhancing patients' quality of life. Attendees will have the opportunity to engage with presenters about the research findings.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.61%
Tags
conferences
Rhea-AI Summary

LivaNova PLC (NASDAQ: LIVN) has received 510(k) clearance from the FDA for its LifeSPARC system, enhancing access to extracorporeal membrane oxygenation (ECMO) for hospitals. This new clearance allows ECMO use beyond six hours for patients in acute respiratory or cardiopulmonary failure, including those affected by COVID-19. LifeSPARC aims to simplify ECMO with a user-friendly design, making it suitable for healthcare facilities of all sizes. The company has a strong track record of 100% customer response to recent updates following a recall.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.52%
Tags
-
Rhea-AI Summary

LivaNova PLC (NASDAQ: LIVN) announces that its CEO, Damien McDonald, will present a business update at three healthcare conferences in New York this month. The conferences include the Stifel Healthcare Conference on November 15, the Wolfe Research Healthcare Conference on November 16, and the Piper Sandler Healthcare Conference on November 29. The Stifel and Piper events will be streamed live, with recordings available afterward, while the Wolfe conference will not be available for streaming. For more details, visit www.livanova.com/events.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.41%
Tags
conferences
-
Rhea-AI Summary

LivaNova PLC (Nasdaq: LIVN) reported a third-quarter 2022 revenue of $252.6 million, a 0.2% decline on a reported basis but 5.2% growth on a constant-currency basis compared to the prior year. A U.S. GAAP diluted loss per share reached $2.01, impacted by a non-cash goodwill impairment charge. Neuromodulation revenue increased by 10.4%, while Cardiopulmonary grew by 6.6%. Advanced Circulatory Support faced a significant 43.8% decline. The company maintains its full-year 2022 revenue growth outlook between 4% and 6% on a constant-currency basis.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.08%
Tags
Rhea-AI Summary

LivaNova PLC (NASDAQ: LIVN) will hold a conference call on November 2, 2022, at 12 p.m. London time (8 a.m. EDT) to discuss its third-quarter 2022 results, releasing the details prior to the call. Interested participants can access a live audiocast at www.livanova.com/events. Call-in options are also available for both U.S. and international listeners. A replay will be offered for 90 days post-call. LivaNova is headquartered in London, employing approximately 3,000 people globally, focusing on innovative medical technologies for patients.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.02%
Tags
-
Rhea-AI Summary

LivaNova PLC (NASDAQ: LIVN) announced the appointment of Brooke Story to its Board of Directors, effective September 15, 2022. Story brings over 20 years of experience in medical technology, currently serving as Worldwide President, Integrated Diagnostic Solutions at BD (NYSE: BDX). She previously held leadership roles at Medtronic, enhancing her expertise in the industry. The Board's Chair, William Kozy, emphasized Story's capability in fostering talent and delivering economic value, which is expected to support LivaNova's growth and innovation strategies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.92%
Tags
management
-
Rhea-AI Summary

LivaNova PLC (Nasdaq: LIVN) reported a 3.9% decline in revenue, totaling $254.2 million for Q2 2022, though constant-currency revenue increased by 0.5%. Excluding the divested Heart Valves business, revenue grew by 1.8% on a reported basis and 6.5% in constant-currency terms. The diluted earnings per share was $0.30, with adjusted diluted EPS at $0.53. The company anticipates a 4-6% revenue growth for full-year 2022 before currency impacts, while foreign exchange is expected to create a 4-5% headwind. Full-year adjusted EPS is projected between $2.25 and $2.45.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.47%
Tags
Rhea-AI Summary

LivaNova PLC (NASDAQ: LIVN) will hold a conference call on August 3, 2022, at 1 p.m. London time (8 a.m. EDT) to discuss its second-quarter 2022 results. The results will be released prior to the call. Interested parties can access a live audiocast on the LivaNova website and also participate via telephone using the specified dialing numbers. A replay will be available for 90 days post-call. LivaNova is a global medical technology company committed to innovative solutions for patients worldwide.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.89%
Tags

FAQ

What is the current stock price of Livanova Plc (LIVN)?

The current stock price of Livanova Plc (LIVN) is $50.69 as of October 10, 2025.

What is the market cap of Livanova Plc (LIVN)?

The market cap of Livanova Plc (LIVN) is approximately 2.8B.
Livanova Plc

Nasdaq:LIVN

LIVN Rankings

LIVN Stock Data

2.85B
54.40M
0.38%
103.73%
3.63%
Medical Devices
Electromedical & Electrotherapeutic Apparatus
Link
United Kingdom
LONDON